Cannabis Law Report

JANUARY 14, 2020

The MORE Act would decriminalize marijuana and THC at the federal level by removing it from Schedule I of the Controlled Substances Act, which currently classifies it as an addictive drug that has no accepted medical use, akin to heroin. 1151, Veterans Medical Marijuana Safe Harbor Act.

Clinical Trials 69

Clinical Trials Programs Access DEA 69

Cannabis Law Report

MARCH 2, 2020

In lockstep with the FDA’s more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Hundreds of other U.S. The dawn of a new era in psychedelic medicine.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” BREAKING: City of Seattle Decriminalizes Psychedelics.

Therapy 98

Therapy Clinical Trials DEA Microdosing 98

Veriheal

DECEMBER 21, 2022

The Drug Enforcement Administration (DEA) is now mandated to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. Rescheduling cannabis and decriminalizing cannabis do not mean the same thing for federal legalization. The law gives the U.S.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Cannabis Law Report

MAY 29, 2022

7] And cities around the country are beginning to decriminalize some psychedelics, with advocates for decriminalization citing the potential medical benefits. In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Canna Law Blog

MARCH 4, 2020

Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine. Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ).

Legalization 55

Legalization Therapy Chronic Pain DEA 55

Canna Law Blog

NOVEMBER 6, 2021

The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA). Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98